Totrombopag is an orally bioavailable, nonpeptide, small-molecule thrombopoietin receptor agonist. It induces proliferation and differentiation of megakaryocytes and progenitor cells, ultimately increasing the production of platelets. Totrombopag has been investigated in healthy volunteers in a phase 1, single-blind, randomized fashion to cause a dosedependent increase in platelet count with demonstrated safety. There were no serious adverse events, no significant changes in laboratory or cardiovascular safety parameters and there was no observed relationship between the incidence or severity of adverse events and dose. Most adverse events were mild in intensity and self-limiting. Totrombopag was developed for the treatment of immune thrombocytopenic purpura.

D-Arabinose (D-Ara) is a reducing rare sugar. It is a substrate for by D-arabinose dehydrogenase (ARA) and participated in D-erythroascorbic acid synthesis in S. cerevisiae. D-Erythroascorbic acid (eAsA) is an important antioxidant molecule in yeast. It was found, that ARA 2p, not ARA 1p, mainly contributes to the production of eAsA. Recently was published the first report of biological of D-Ara. It was compared the growth inhibitory effects of aldohexose stereoisomers against the animal model Caenorhabditis elegans cultured in monoxenic conditions with Escherichia coli as food. The inhibitory effect of D-Ara was also observed in animals cultured in axenic conditions using a chemically defined medium; this excluded the possible influence of E. coli. Among these stereoisomers, the D-Ara showed particularly strong growth inhibition. The assumption was made pointing, that the inhibition could be induced by multiple mechanisms, for example, disturbance of D-ribose and D-fructose metabolism.

Anamorelin is a first-in-class, orally active ghrelin receptor agonist that binds and stimulates the growth hormone secretagogue receptor centrally, thereby mimicking the appetite-enhancing and anabolic effects of ghrelin. Anamorelin is under development by Helsinn Therapeutics for the treatment of cancer cachexia and anorexia. Anamorelin has completed phase III clinical trials for the treatment of cancer cachexia and anorexia associated with non-small-cell lung carcinoma. Results of the studies were positive, and the drug is now in preregistration with the European Medicines Agency.